- Home
- ITGR vs LEGN Comparison
ITGR vs LEGN Comparison
Compare ITGR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITGR | LEGN |
|---|---|---|
| Founded | 1970 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.6B |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ITGR | LEGN |
|---|---|---|
| Price | $126.66 | $17.42 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $127.00 | $42.46 |
| AVG Volume (30 Days) | 693.9K | ★ 2.3M |
| Earning Date | 10-29-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.60 | N/A |
| Revenue | ★ $1,853,637,000.00 | N/A |
| Revenue This Year | N/A | $38.71 |
| Revenue Next Year | $5.98 | $18.83 |
| P/E Ratio | $79.11 | ★ N/A |
| Revenue Growth | ★ 7.98 | N/A |
| 52 Week Low | $66.51 | $16.24 |
| 52 Week High | $126.83 | $37.50 |
Technical Indicators
Market Signals| Indicator | ITGR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.45 | 37.79 |
| Support Level | $126.50 | $17.43 |
| Resistance Level | $126.80 | $19.92 |
| Average True Range (ATR) | 0.17 | 1.50 |
| MACD | -0.06 | -0.47 |
| Stochastic Oscillator | 46.03 | 1.15 |
Price Performance
Historical ComparisonAbout ITGR Integer Holdings Corporation
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.